CCR3 and rheumatoid arthritis: Corresponding proteins from many of these DEGs have already been identified as drug targets for the treatment of various diseases such as COVID-19, asthma or rheumatoid arthritis (e.g., CCR2, CCR3, CXCL8, JAK3, HRH, CA4, see clinicaltrials.gov).